TxCell plans first-in-man trial of regulatory T cells

May 18, 2017 Christoph Graener

Having completed a Phase I/IIa study of Ovasave, a drug candidate from its first generation non-modified antigen-specific regulatory T cells (Tregs), TxCell expects to start a first-in-man study of a candidate from its next generation Treg platform in 2018. Mr. Stephane Boissel, TxCell’s CEO, explained to Scrip’s Mike Ward why the company accelerated its new platform and how it intends to focus on inflammatory and autoimmune diseases.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Stéphane Boissel – CEO, TxCell

Previous Article
Covance: Expedited drug development with a new programmatic model
Covance: Expedited drug development with a new programmatic model

Drug development is undergoing a major transformation in order to align with the new norma—replacing a tran...

Next Article
Mitochondrial medicine focus drives NeuroVive orphan ambitions

Underpinned by a profound understanding of genetic mitochondrial disorders, Swedish biotech NeuroVive Pharm...